WO2014106001A3 - Protéines de liaison doublement spécifiques ayant une séquence récepteur - Google Patents

Protéines de liaison doublement spécifiques ayant une séquence récepteur Download PDF

Info

Publication number
WO2014106001A3
WO2014106001A3 PCT/US2013/077908 US2013077908W WO2014106001A3 WO 2014106001 A3 WO2014106001 A3 WO 2014106001A3 US 2013077908 W US2013077908 W US 2013077908W WO 2014106001 A3 WO2014106001 A3 WO 2014106001A3
Authority
WO
WIPO (PCT)
Prior art keywords
binding proteins
specific binding
dual specific
receptor sequence
receptor
Prior art date
Application number
PCT/US2013/077908
Other languages
English (en)
Other versions
WO2014106001A2 (fr
Inventor
Tariq Ghayur
Philip Bardwell
Original Assignee
Abbvie, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie, Inc. filed Critical Abbvie, Inc.
Priority to EP13824268.0A priority Critical patent/EP2938634A2/fr
Publication of WO2014106001A2 publication Critical patent/WO2014106001A2/fr
Publication of WO2014106001A3 publication Critical patent/WO2014106001A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Optics & Photonics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)

Abstract

L'invention concerne des protéines de liaison multi-spécifiques génétiquement modifiées qui se lient à au moins un ligand pour un récepteur, ainsi que des procédés de fabrication et des utilisations dans la prévention, le diagnostic et/ou le traitement d'une maladie.
PCT/US2013/077908 2012-12-28 2013-12-27 Protéines de liaison doublement spécifiques ayant une séquence récepteur WO2014106001A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP13824268.0A EP2938634A2 (fr) 2012-12-28 2013-12-27 Protéines de liaison doublement spécifiques ayant une séquence récepteur

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261746616P 2012-12-28 2012-12-28
US61/746,616 2012-12-28

Publications (2)

Publication Number Publication Date
WO2014106001A2 WO2014106001A2 (fr) 2014-07-03
WO2014106001A3 true WO2014106001A3 (fr) 2014-08-28

Family

ID=50001284

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/077908 WO2014106001A2 (fr) 2012-12-28 2013-12-27 Protéines de liaison doublement spécifiques ayant une séquence récepteur

Country Status (3)

Country Link
US (2) US20140219913A1 (fr)
EP (1) EP2938634A2 (fr)
WO (1) WO2014106001A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012228248A (ja) * 2005-08-19 2012-11-22 Abbott Lab 二重可変ドメイン免疫グロブリン及びその使用
AR082461A1 (es) 2010-08-03 2012-12-12 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US9856319B2 (en) 2012-12-28 2018-01-02 Abbvie Inc. Monovalent binding proteins
KR20160113268A (ko) * 2014-01-28 2016-09-28 베이징 한미 파마슈티컬 컴퍼니 리미티드 이기능 융합단백질,이의 제조방법 및 용도
WO2015114150A1 (fr) 2014-02-02 2015-08-06 Medimmune Limited PROTÉINE CHIMÉRIQUE COMPOSÉE D'UN DOMAINE ANTAGONISTE DE NGF ET D'UN DOMAINE ANTAGONISTE DE TNFα
WO2015191934A2 (fr) 2014-06-11 2015-12-17 Abbvie Inc. Barrière hémato-encéphalique pénétrant des protéines de liaison spécifiques doubles pour le traitement de maladies cérébrales et neurologiques
WO2016094881A2 (fr) 2014-12-11 2016-06-16 Abbvie Inc. Protéines de liaison à lrp-8
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
ES2878008T3 (es) * 2015-09-17 2021-11-18 Scripps Research Inst Inmunoconjugados de dominio variable dual y usos de los mismos
WO2017189964A2 (fr) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions pour le traitement de maladies
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2019152808A1 (fr) * 2018-02-01 2019-08-08 Yale University Compositions et procédés d'inhibition d'anticorps pénétrant dans le noyau
EP4308608A1 (fr) 2021-03-16 2024-01-24 JN Biosciences LLC Molécules bifonctionnelles pour le traitement de troubles immunitaires
PL244818B1 (pl) * 2021-11-03 2024-03-11 Urteste Spolka Z Ograniczona Odpowiedzialnoscia Związek-marker diagnostyczny raka wątroby, sposób wykrywania aktywności enzymatycznej, sposób diagnozowania raka wątroby, zestaw zawierający taki związek oraz związek do zastosowania medycznego

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016437A1 (fr) * 1990-04-25 1991-10-31 The Johns Hopkins University Analogues de peptides solubles contenant des sites de liaison
WO2009149189A2 (fr) * 2008-06-03 2009-12-10 Abbott Laboratories Immunoglobulines à deux domaines variables et leurs utilisations
WO2010003108A2 (fr) * 2008-07-02 2010-01-07 Trubion Pharmaceuticals, Inc. Protéines de liaison multi-cibles antagonistes du tnf-α
WO2010006060A2 (fr) * 2008-07-08 2010-01-14 Abbott Laboratories Immunoglobulines à double domaine variable de prostaglandine e2 et leurs utilisations
WO2012121775A2 (fr) * 2010-12-21 2012-09-13 Abbott Laboratories Immunoglobulines à double domaine variable et leurs utilisations
WO2012169822A2 (fr) * 2011-06-10 2012-12-13 강원대학교산학협력단 Protéine de fusion permettant de supprimer la croissance des cellules cancéreuses et la vasculogenèse et composition anticancéreuse la contenant
WO2012172521A1 (fr) * 2011-06-16 2012-12-20 Novartis Ag Protéines solubles destinées à être utilisées comme agents thérapeutiques

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
WO1988007089A1 (fr) 1987-03-18 1988-09-22 Medical Research Council Anticorps alteres
US5006309A (en) 1988-04-22 1991-04-09 Abbott Laboratories Immunoassay device with liquid transfer between wells by washing
US5089424A (en) 1988-06-14 1992-02-18 Abbott Laboratories Method and apparatus for heterogeneous chemiluminescence assay
US5063081A (en) 1988-11-14 1991-11-05 I-Stat Corporation Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor
CA2069530A1 (fr) 1991-06-03 1992-12-04 Cass J. Grandone Trousse de reactifs pour dosages immunologiques
BRPI9715219B8 (pt) 1996-02-09 2015-07-07 Abbvie Biotechnology Ltd Vetor recombinante de expressão, e célula hospedeira procariótica.
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
JP4955185B2 (ja) * 2000-06-29 2012-06-20 アボット・ラボラトリーズ 二重特異性抗体ならびに作製方法および使用方法
US7419821B2 (en) 2002-03-05 2008-09-02 I-Stat Corporation Apparatus and methods for analyte measurement and immunoassay
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
US20040018577A1 (en) 2002-07-29 2004-01-29 Emerson Campbell John Lewis Multiple hybrid immunoassay
WO2004014905A1 (fr) * 2002-08-08 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Composes benzimidazole substitues
CA2537055A1 (fr) 2003-08-22 2005-04-21 Medimmune, Inc. Humanisation d'anticorps
US7723099B2 (en) 2003-09-10 2010-05-25 Abbott Point Of Care Inc. Immunoassay device with immuno-reference electrode
US7682833B2 (en) 2003-09-10 2010-03-23 Abbott Point Of Care Inc. Immunoassay device with improved sample closure
US7537930B2 (en) * 2004-07-23 2009-05-26 Immunomedics, Inc. Mammalian cell lines for increasing longevity and protein yield from a cell culture
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AU2009206089B2 (en) 2008-01-15 2014-08-28 Abbvie Inc. Improved mammalian expression vectors and uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016437A1 (fr) * 1990-04-25 1991-10-31 The Johns Hopkins University Analogues de peptides solubles contenant des sites de liaison
WO2009149189A2 (fr) * 2008-06-03 2009-12-10 Abbott Laboratories Immunoglobulines à deux domaines variables et leurs utilisations
WO2010003108A2 (fr) * 2008-07-02 2010-01-07 Trubion Pharmaceuticals, Inc. Protéines de liaison multi-cibles antagonistes du tnf-α
WO2010006060A2 (fr) * 2008-07-08 2010-01-14 Abbott Laboratories Immunoglobulines à double domaine variable de prostaglandine e2 et leurs utilisations
WO2012121775A2 (fr) * 2010-12-21 2012-09-13 Abbott Laboratories Immunoglobulines à double domaine variable et leurs utilisations
WO2012169822A2 (fr) * 2011-06-10 2012-12-13 강원대학교산학협력단 Protéine de fusion permettant de supprimer la croissance des cellules cancéreuses et la vasculogenèse et composition anticancéreuse la contenant
WO2012172521A1 (fr) * 2011-06-16 2012-12-20 Novartis Ag Protéines solubles destinées à être utilisées comme agents thérapeutiques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LARSEN C P ET AL: "Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties", AMERICAN JOURNAL OF TRANSPLANTATION, BLACKWELL MUNKSGAARD, DK, vol. 5, no. 3, 1 March 2005 (2005-03-01), pages 443 - 453, XP002393471, ISSN: 1600-6135, DOI: 10.1111/J.1600-6143.2005.00749.X *

Also Published As

Publication number Publication date
WO2014106001A2 (fr) 2014-07-03
US20140219913A1 (en) 2014-08-07
EP2938634A2 (fr) 2015-11-04
US20170096470A1 (en) 2017-04-06

Similar Documents

Publication Publication Date Title
WO2014106001A3 (fr) Protéines de liaison doublement spécifiques ayant une séquence récepteur
WO2013101993A3 (fr) Immunoglobulines à double domaine variable et leurs utilisations
WO2014089209A3 (fr) Protéines de liaison à double spécificité pénétrant la barrière hémato-encéphalique (bbb)
WO2014144280A8 (fr) Protéines de liaison spécifiques à domaines variables doubles dirigées contre il -1β et/ou il -17
WO2012061558A3 (fr) Immunoglobulines à double domaine variable et leurs utilisations
WO2012061374A3 (fr) Immunoglobulines à double domaine variable et utilisations de celles-ci
WO2012027570A3 (fr) Immunoglobulines à deux domaines variables et leurs utilisations
WO2012018790A3 (fr) Immunoglobulines à double domaine variable et utilisations associées
WO2014144299A3 (fr) Protéines de liaison spécifiques à domaines variables doubles dirigées contre tnfα
WO2013119966A3 (fr) Anticorps et autres hétéromultimères monocaténaires
HK1202557A1 (en) Antibodies against claudin 18.2 useful in cancer diagnosis 18.2
WO2013102042A3 (fr) Protéines à double liaison spécifique dirigées contre l'il-13 et/ou l'il-17
EP2590671A4 (fr) Immunoglobulines à domaine variable double et leurs utilisations
WO2012088290A3 (fr) Protéines de liaison à trois domaines variables et leurs utilisations
WO2013101972A3 (fr) Immunoglobulines à domaine variable double et applications associées
WO2012121775A3 (fr) Immunoglobulines à double domaine variable et leurs utilisations
WO2011163478A3 (fr) Immunoglobulines à double domaine variable et utilisations associées
PH12014501108A1 (en) Anti-il-36r antibodies
PH12014502406A1 (en) Anti-il-23p19 antibodies
WO2013049517A3 (fr) Peptides thérapeutiques
WO2015051379A3 (fr) Protéines de liaison spécifiques doubles dirigées contre des récepteurs de cellules immunitaires et des auto-antigènes
TN2014000207A1 (en) Anti il-36r antibodies
NZ626513A (en) Anti-cd98 antibodies and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13824268

Country of ref document: EP

Kind code of ref document: A2

REEP Request for entry into the european phase

Ref document number: 2013824268

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2013824268

Country of ref document: EP